In Current oncology (Toronto, Ont.)
BACKGROUND : The aim of our study was to develop a radiomic tool for the prediction of clinically significant prostate cancer.
METHODS : From September 2020 to December 2021, 91 patients who underwent magnetic resonance imaging prostate fusion biopsy at our institution were selected. Prostate cancer aggressiveness was assessed by combining the three orthogonal planes-Llocal binary pattern the 3Dgray level co-occurrence matrix, and other first order statistical features with clinical (semantic) features. The 487 features were used to predict whether the Gleason score was clinically significant (≥7) in the final pathology. A feature selection algorithm was used to determine the most predictive features, and at the end of the process, nine features were chosen through a 10-fold cross validation.
RESULTS : The feature analysis revealed a detection accuracy of 83.5%, with a clinically significant precision of 84.4% and a clinically significant sensitivity of 91.5%. The resulting area under the curve was 80.4%.
CONCLUSIONS : Radiomic analysis allowed us to develop a tool that was able to predict a Gleason score of ≥7. This new tool may improve the detection rate of clinically significant prostate cancer and overcome the limitations of the subjective interpretation of magnetic resonance imaging, reducing the number of useless biopsies.
Prata Francesco, Anceschi Umberto, Cordelli Ermanno, Faiella Eliodoro, Civitella Angelo, Tuzzolo Piergiorgio, Iannuzzi Andrea, Ragusa Alberto, Esperto Francesco, Prata Salvatore Mario, Sicilia Rosa, Muto Giovanni, Grasso Rosario Francesco, Scarpa Roberto Mario, Soda Paolo, Simone Giuseppe, Papalia Rocco
2023-Feb-07
clinically significant, machine-learning, prostate biopsy, prostate cancer, radiomic
